All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

PHARMACOMPASS

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

Product Type

Companies

Engitix Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Engitix Signs Collaboration and Licensing Agreement with Takeda to Develop Anti-Fibrotic Therapies in Advanced Liver Diseases

Lead Product(s): Undisclosed

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

Highest Development Status: Discovery Platform Product Type: Undisclosed

Partner/Sponsor/Collaborator: Takeda Pharmaceutical

Deal Size: $500.0 million Upfront Cash: Undisclosed

Deal Type: Licensing Agreement August 25, 2020

Details:

Under the terms of the agreement, Takeda will have exclusive rights to develop and commercialise clinical candidates generated against validated targets derived from the collaboration.